Veerhealth Care has received a confirmed order valued at Rs 454.68 lakh for the supply of face care products. The order was disclosed to the exchange on October 3, 2026.

ORDER DETAILS

The awarding entity is a domestic company whose identity is not disclosed as per confidential terms. The order classification is marked as Significant. The contract terms specify that the supply of face care products must be executed within a period of 45 days. The transaction does not involve related party interests or promoter interest.

ORDER IN FINANCIAL CONTEXT

The Rs 454.68 lakh order value cannot be meaningfully benchmarked against average quarterly revenue, as the pre-computed average quarterly revenue is Rs 0.0 crore based on TTM data. Consequently, the book-to-bill ratio remains mathematically undefined due to zero denominator revenue. This disparity highlights that while order inflow is active, revenue recognition has not yet commenced or reported at scale.

COMPANY ORDER TRACK RECORD

Order inflow velocity has accelerated in the latest quarter. Q2FY27 saw total inflows of Rs 1143.54 crore, a sharp increase from Rs 149.05 crore in Q1FY27. The company has now received orders from multiple entity types, including domestic and entities not disclosed as per confidential terms.

ORDER HISTORY

EXECUTION AND REVENUE QUALITY

The company reports zero consolidated revenue, net profit, and operating profit margin for the trailing twelve months. This indicates that existing backlogs are not currently converting to recognized revenue in the audited financials provided.

WORKING CAPITAL AND EXECUTION CAPACITY

Balance sheet and cashflow data are not explicitly provided in the input for detailed liquidity analysis. With zero operating cashflow and zero revenue, the company's ability to fund working capital for the existing backlog depends entirely on external financing or promoter support. The absence of reported liabilities or equity figures prevents a precise current ratio assessment, but the lack of revenue generation poses a fundamental working capital constraint until orders begin converting to billings.

WHAT TO WATCH

• Execution rate: Quarterly revenue run-rate vs total backlog is currently zero; watch for the first instance of revenue recognition to validate execution capability.
• Margin quality: OPM trajectory on new orders vs historical average is unobservable; initial revenue filings will reveal whether these contracts carry healthy margins.
• Client concentration: A significant portion of the order book comes from entities listed as "Not disclosed as per confidential terms," making it difficult to assess true client concentration risk beyond the named partners.
• Revenue recognition lag: The gap between Rs 1143.54 crore in recent order inflows and Rs 0.0 crore in TTM revenue requires monitoring to ensure orders are translating into billable milestones.
• Entity diversity: Veerhealth Care has now received orders from domestic and undisclosed counterparties across the last two fiscal quarters.

KEY OBSERVATIONS

• Valuation check (as of 03 Oct 2026): P/E of 64.4x against ROCE of 5.4%. Valuation is pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
• Backlog signal: Book-to-bill is undefined due to zero TTM revenue. At this level, execution capacity becomes the binding constraint, as the entire order book must be converted to revenue to justify current market expectations.

Veerhealth Care Ltd disclosed voting results for its 34th Annual General Meeting held on September 23, 2026, confirming both ordinary resolutions passed with requisite majority, with 99.99% of valid votes cast in favour of each.

The meeting was conducted via video conferencing, commencing at 4:00 pm and concluding at 4:23 pm. A total of 84 shareholders attended through video conferencing, comprising 5 from the promoter and promoter group and 79 from the public category. As on the record date of September 16, 2026, there were 9,450 shareholders on record.

Agenda items resolved

Shareholders passed two ordinary resolutions: adoption of the audited financial statements for the fiscal year ended March 31, 2026, along with the Board's report and auditors' report; and the reappointment of Mrs. Shruti A Shah (DIN: 06952245), who retired by rotation and offered herself for reappointment.

The auditors issued an unqualified opinion with no adverse remarks or material qualifications. The secretarial audit report similarly contained no adverse comments.

Voting results

Scrutinizer Khushboo Shah submitted a consolidated report covering remote e-voting and e-voting conducted at the AGM. The voting results for both resolutions were identical, as detailed below.

For each resolution, 132 members voted in favour, casting 6,849,976 votes representing 99.99% of valid votes polled. Two members voted against, casting 101 votes representing 0.01% of valid votes polled. No invalid votes were recorded across any category.

Voting process and scrutinizer details

Remote e-voting opened on September 20, 2026, at 9:00 am and closed on September 22, 2026, at 5:00 pm on the NSDL e-voting platform. An additional 15-minute window for live e-voting remained open during the meeting. The e-votes were unblocked on September 24, 2026, following the conclusion of the AGM.

Mr. Yogesh M Shah chaired the session as Non-Executive Non-Independent Director and Chairperson. Key personnel present included Bhavin Shah (Managing Director), Akash Shah (Chief Financial Officer), and Ruchi Shah (Company Secretary). Statutory auditors from Jayesh Shah & Associates and secretarial auditors from Nidhi Shah & Associates also attended.